

CTS SCIENTIFIC PROGRAM 2024

Monday October 7, 2024, 08:00 – 14:30
 Held in conjunction with CHEST Annual Meeting
 Room 258C, Boston Convention and Exhibition Centre

Program Chair: Dr. Christopher A Hergott

Session 1 **Pleural Disease, ILD and Sleep Medicine - Cutting Edge Updates from Early Career Faculty – Canadian Thoracic Society (CTS)**

08:00 – 08:20	Pleural Disease Diagnosis and Management update <i>William Liang, MD, FRCPC, University of Manitoba, Winnipeg, MB</i> <p>Pleural effusions can sometimes remain a diagnostic dilemma. We will discuss the diagnosis testing of various causes of pleural effusions. We will also discuss the management of different types of effusions. At the end of this session, participants will be able to:</p> <ol style="list-style-type: none"> 1. Select diagnostic tests associated with pleural effusions 2. Differentiate causes of pleural effusions 3. Discuss short and long term management of pleural effusions <p>Dr. William Liang is an Assistant Professor at the University of Manitoba. He completed an Interventional Pulmonology fellowship at the University of Calgary. He works as an Interventional Pulmonologist and chronic mechanical ventilation specialist at Health Sciences Centre and Saint Boniface hospitals of Winnipeg.</p>
08:20 – 08:40	Inhalational Exposures and Interstitial Lung Disease <i>Stacey Lok, MD, FRCPC, University of Saskatchewan, Saskatoon, SK</i> <p>Many fibrotic interstitial lung disease (fILD) subtypes are associated with inhaled environmental or occupational exposures and high prevalence of organic and inorganic exposures are found even in non-exposure related fILD. This talk will examine the identification of exposures and its relationship with diagnosis, management, and prognosis in fILD. At the end of this session, participants will be able to:</p> <ol style="list-style-type: none"> 1. Identify risk factors for inhalational exposures 2. Describe the effects of inhalational exposures on radiologic features in fILD 3. Summarize the relationship between inhalational exposures and outcomes in fILD subtypes <p>Dr. Stacey Lok is an Assistant Professor in the Division of Respiriology, Critical Care, and Sleep Medicine at the University of Saskatchewan. She completed her undergraduate medical training, internal medicine and respirology residency at the University of Saskatchewan followed by an Interstitial Lung Disease fellowship at the University of Calgary. She was a recipient of the Canadian Pulmonary Fibrosis Foundation Robert Davidson Fellowship. Her primary clinical and research interest is in interstitial lung disease and she is an investigator for the Canadian Registry for Pulmonary Fibrosis.</p>
08:40 – 09:00	Latest Updates in Sleep Medicine in Canada <i>Alyssa Lip, MD, FRCPC, DRCPC, University of Calgary, Calgary, AB</i> <p>This session will provide an overview of sleep disorder epidemiology and impact in Canada, along with a brief update of recent advances and insights into treatment of common sleep disorders. At the end of this session, participants will be able to:</p> <ol style="list-style-type: none"> 1. Update on the most recent estimated burden of sleep disorders in Canada 2. Recognize novel pharmacologic and non-pharmacologic treatment options for common sleep disorders 3. Describe the current state of sleep education in Canada <p>Dr. Alyssa Lip is a clinical assistant professor with the Division of Respiriology at the University of Calgary and concurrently completing a Master of Health Profession Education. She is a respirologist and sleep specialist, with a particular interest in improving health outcomes through the development and study of education interventions.</p>

09:00 – 09:15	Break
Session 2	Canadian Thoracic Society (CTS) 2024 Honorary Lecture: How One Becomes a Sarcoidologist: A Tale of Serendipity, Community, and Mentorship
09:15 – 10:15	<p>CTS 2024 Honorary Lecture: How One Becomes a Sarcoidologist: A Tale of Serendipity, Community, and Mentorship</p> <p><i>Meyer Balter, MD, FRCPC, University of Toronto, Toronto, ON</i></p> <p>Diagnosis and therapy of select manifestations of sarcoidosis will be discussed using patient examples from my clinical practice with an emphasis on cardiac and pulmonary fibrotic manifestations of the disease. At the end of this session, participants will be able to:</p> <ol style="list-style-type: none"> 1. Describe the role for novel methods for determining sarcoidosis activity 2. Determine which sarcoidosis patients require systemic therapy 3. Understand the diagnosis and treatment of cardiac involvement by sarcoidosis <p>Dr. Meyer Balter obtained his Medical Degree from McGill University in 1981. After completing his Internal Medicine training at McGill, he went on to complete a Pulmonary and Critical Care Fellowship at the University of Michigan in 1988. He then moved to the University of Toronto where he is currently a Professor of Medicine. He is the Director of the Asthma and COPD Education Clinic at Mount Sinai Hospital. His clinical interests include asthma, COPD and sarcoidosis. He was previously on the CTS Guideline Committees for both asthma and COPD and currently is on the executive for the Americas Association of Sarcoidosis and Other Granulomatous diseases (AASOG).</p>
10:15 – 11:00	Break
Session 3	Respiratory Oscillometry and the Canadian TB Standards - What's New and What Need to Know – Canadian Thoracic Society (CTS)
11:00 – 11:30	<p>Respiratory Oscillometry: Ready for Prime Time in the Clinic?</p> <p><i>Chung Wai Chow, MD, PhD, FRCPC, University of Toronto, Toronto, ON</i></p> <p>This talk will provide a summary of what respiratory oscillometry measures and put it in the context of the current arsenal of pulmonary function test modalities. We review the current literature in different respiratory diseases and guidelines for conduct of oscillometry. At the end of this session, participants will be able to:</p> <ol style="list-style-type: none"> 1. Understand what oscillometry measures 2. Recognize the different oscillometry patterns of different respiratory physiology 3. Identify clinical scenarios where oscillometry can be helpful in patient management <p>Chung-Wai Chow is a Professor of Medicine and Division Director of Respiriology at the University of Toronto. She is a transplant respirologist and Clinician-Scientist at the University Health Network. She holds the Pettit Chair of Respiratory Medicine. She completed her MD and PhD at the University of Toronto in Adult Respiratory Medicine and Cell Biology, respectively before a Postdoctoral Fellowship at the Max Planck Institute, Germany as an Alexander von Humboldt Fellow. Her research is focused on the development of novel techniques to assess lung function using respiratory oscillometry and development of machine learning techniques to improve diagnostic acumen. She leads several large prospective studies that compare respiratory oscillometry with spirometry in different patient populations.</p>
11:30 – 12:00	<p>Canadian Tuberculosis Standards: Update on Treatment</p> <p><i>Dina Fisher, MSc, MD, FRCPC, University of Calgary, Calgary, AB</i></p> <p>This session will provide updates on the 2022 Canadian Tuberculosis Standards and beyond. We will review the Canadian Standards and recent studies for TB treatment, Multidrug-resistant TB (MDRTB) treatment as well as the treatment options for TB prevention. At the end of this session, participants will be able to:</p> <ol style="list-style-type: none"> 1. Summarize the recent Canadian Standards for TB Treatment 2. Review the recent Canadian Standards for MDRTB Treatment 3. Summarize the Canadian Standards for TB Preventive Treatment <p>Dr. Dina Fisher is a Clinical Professor of Medicine in the Departments of Medicine and Community Health Sciences, University of Calgary. She is the current site lead for the Peter Lougheed Centre, Division of Respiratory Medicine and the Medical Director for the Calgary TB clinic. Dina has been an author of two chapters on extra pulmonary tuberculosis in the 7th, and 8th editions of the Canadian TB Standards (2013 and 2022, respectively). Dina has graduate training in epidemiology and is an award-winning instructor – these strengths are leveraged in her research portfolio particularly in the area of clinical trials, and incorporating knowledge gleaned from patient perspectives in the provision of TB services.</p>

12:00 – 13:30	Lunch Break
Session 4	Pro/Con Debate: Triple Inhaled Therapy Provides Benefits for Mortality in COPD – Canadian Thoracic Society (CTS)
13:30 – 14:30	<p>Pro/Con Debate: Triple Inhaled Therapy Provides Benefits for Mortality in COPD <i>Pro: Darcy Marciniuk, MD, FRCPC, FCAHS, Master FCCP, University of Saskatchewan, Saskatoon, SK</i> <i>Con: Jean Bourbeau, MD, MSc, FRCPC, FCAHS, McGill University, Montreal, QC</i></p> <p>This pro and con debate will highlight and discuss data from the scientific literature in COPD, with an evidence base ranging from randomized-controlled trials (RCTs) to real-world evidence (RWE) studies, to illuminate the facets of COPD management that will lead to improved patient care and outcomes.</p> <p>There have been differences of interpretation and opinion based on recent data from randomized clinical trials and real-world evidence studies. We are of the opinion that it is best to present these differences and explore all sides of debated issues.</p> <p>At the end of the debate the audience will be fully aware of the published literature and recent controversies, have an excellent understanding of what is relevant to both clinicians and patients, and have gained mastery regarding important, and achievable, clinical outcomes.</p> <p>The debate will be spirited at the beginning, but at the end we hope everyone will agree that the patient should win!</p> <p>At the end of the session, participants will be able to:</p> <ol style="list-style-type: none"> 1. Summarize what the current trials have accomplished and <ol style="list-style-type: none"> a. the potential problem, i.e., the wrong trial may have been conducted, and b. the cautions against extrapolations from these trials; 2. Discuss why FDA didn't recommend triple therapy for mortality reduction in COPD; 3. Review the increased pneumonia risk as a serious adverse event. <p>Dr. Jean Bourbeau is a clinician scientist, professor, and researcher at McGill University and a Senior Scientist at the Research Institute McGill University Health Centre. He is a Fellow of the Canadian Academy of Health Sciences (FCAHS) and has received numerous prestigious awards. He is known for his expertise in Chronic Obstructive Pulmonary Disease (COPD), he actively participates in various scientific committees, including the scientific committee of GOLD, and has one of the lead authors on the 2023 CTS COPD Pharmacotherapy Guideline.</p> <p>Dr. Darcy Marciniuk is Associate Vice-President Research at the University of Saskatchewan and Medical Director of the LiveWell COPD Management Program in the Saskatchewan Health Authority. He is recognized internationally as an expert and leader, with more than 480 invited national and international presentations, and 250 peer-reviewed publications. He is a past President of the CTS and the American College of Chest Physicians, and past Chair of the Forum of International Respiratory Societies. Dr. Marciniuk has led and participated in many COPD, CPET and Pulmonary Rehabilitation guidelines and recently chaired a multi-society international guideline on race and pulmonary function testing.</p>
17:00 – 18:30	CTS Members' Reception (by invitation) Omni Boston Hotel at the Seaport, Room: ENSEMBLE E